Eplerenone cleared subretinal fluid faster in acute central serous chorioretinopathy, without a visual gain

The edition in brief

In a double-masked trial of 44 patients with first-episode acute central serous chorioretinopathy, oral eplerenone 25 mg twice daily for three months led to greater subretinal fluid absorption than placebo (P < 0.05) and better choriocapillaris perfusion on OCT angiography, but visual acuity improved similarly in both groups. In a 198-participant trial in geographic atrophy, gildeuretinol did not meet its primary endpoint of lesion growth (difference -0.25 mm² per year, 95% CI -0.53 to 0.03; P = 0.075); secondary and sensitivity analyses with nominal P values favoured it and are exploratory. The FDA database lists a supplement to a generic tafluprost application from Micro Labs; the record does not say what changed. A meta-analysis of 136 mostly case-report studies found a pooled 83% response after switching biologic in anti-TNF-refractory noninfectious uveitis, with higher response after switching to a different class (89%) than to another anti-TNF agent (77%), on low-certainty evidence.